Grüter, Thomas
Behrendt, Volker
Bien, Corinna I.
Gold, Ralf
Ayzenberg, Ilya http://orcid.org/0000-0002-6009-792X
Article History
Received: 24 March 2020
Revised: 12 May 2020
Accepted: 14 May 2020
First Online: 22 May 2020
Compliance with ethical standards
:
: Dr. Grüter received travel reimbursement from Sanofi Genzyme and Biogen Idec, none related to this manuscript. Dr. Bien reports no disclosures. Dr. Behrendt reports no disclosures. Prof. Gold serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. Dr. Ayzenberg received travel grants from Biogen Idec and Guthy-Jackson Charitable Foundation, served on scientific advisory boards for Roche and Alexion and received research support from Chugai Pharma and Diamed, none related to this manuscript.
: The authors received written consent from participants in this case report prior to their inclusion in the study and have them on file in case they are requested by the editor. The manuscript does not contain clinical or animal studies.
: The authors received written consent from participants in this case report prior to their inclusion in the study and have them on file in case they are requested by the editor.
: Dr. Ayzenberg has full access to all of the data, and the right to publish any and all data separate and apart from any sponsor. All authors have approved the final submitted version.